Form 4: Rigel Pharmaceuticals Director Ali-Jackson Kamil Reports Acquisition of Shares and Stock Options

Director Ali-Jackson Kamil reports acquisition of 25,000 common stock shares and 30,000 stock options in Rigel Pharmaceuticals.

Summary

• On May 25, 2024, Ali-Jackson Kamil, a director of Rigel Pharmaceuticals, reported acquiring 25,000 shares of common stock upon the vesting of a Restricted Stock Unit award.
• The shares were acquired at a price of $0.
• Following the transaction, Ali-Jackson Kamil beneficially owns 68,750 shares of common stock.
• Additionally, Ali-Jackson Kamil acquired 30,000 stock options with an exercise price of $0.9075.
• These options vest monthly over one year from the grant date and expire on May 25, 2034.
• Following the transaction, Ali-Jackson Kamil beneficially owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction report. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. These filings are closely watched by investors to gauge sentiment among company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates